Beard SM, Wall L, Gaffney L, Sampson F. Aggressive non-Hodgkin's lymphoma: economics of high-dose therapy. Pharmacoeconomics. 2004 Jan 1;22(4):207-24.
Sapienza S, Sacco P, Floyd K, DiCesare J, Doan Q. Results of a pilot pharmacotherapy quality improvement program using fixed-dose, combination amlodipine/benazepril antihypertensive therapy in a long-term care setting. Clin Ther. 2003 Jun;25(6):1872-87.
Bradley RH, National Institute of Child Health and Human Development (NICHD) Early Child Care Research Network, McLeod LD. Child care and common communicable illnesses in children aged 37 to 54 months. Arch Pediatr Adolesc. 2003 Feb;157(2):196-200. doi: 10.1001/archpedi.157.2.196
Bann CM, Fehnel S, Gagnon DD. Development and validation of the diabetic foot ulcer scale-short form (DFS-SF). Pharmacoeconomics. 2003 Jan 1;21(17):1277-90.
Earnshaw SR, Dennett SL. Integer/linear mathematical programming models: a tool for allocating healthcare resources. Pharmacoeconomics. 2003 Jan 1;21(12):839-51.
McLeod LD, Fehnel SE, Brandman J, Symonds T. Evaluating minimal clinically important differences for the acne-specific quality of life questionnaire. Pharmacoeconomics. 2003 Jan 1;21(15):1069-79.
Mauskopf JA, Cates SC, Griffin AD, Neighbors DM, Lamb SC, Rutherford C. Cost-effectiveness of zanamivir for the treatment of influenza in a high-risk population in Australia. Pharmacoeconomics. 2000 Jun;17(6):611-20. doi: 10.2165/00019053-200017060-00007.
Sculpher M, Palmer MK, Heyes AE. Costs incurred by patients undergoing advanced colorectal cancer therapy. A comparison of raltitrexed and fluorouracil plus folinic acid. Pharmacoeconomics. 2000 Apr;17(4):361-70.
Caro JJ, Klittich WS, Raggio G, Kavanagh PL, O'Brien JA, Shomphe LA, Flegel KM, Copley-Merriman C, Sigler C. Economic assessment of troglitazone as an adjunct to sulfonylurea therapy in the treatment of type 2 diabetes. Clin Ther. 2000 Jan;22(1):116-27.
McKenna SP, Doward LC. A review of quality of life in Alzheimer's disease. Parts 1 and 2: issues in assessing disease impact and drug effects. Pharmacoeconomics. 1999 Oct;16(4):417-9.
Whalley D, McKenna SP. Measuring quality of life in patients with depression or anxiety. Pharmacoeconomics. 1995 Oct;8(4):305-15.
McKenna SP, Doward LC. Quality-of-life assessment of adults with growth hormone deficiency: implications for drug therapy. Pharmacoeconomics. 1994 Nov 1;6(5):434-41.